参芪平喘颗粒治疗慢性肺源性心脏病缓解期的临床疗效观察

参芪平喘颗粒治疗慢性肺源性心脏病缓解期的临床疗效观察【摘要】目的：探讨参芪平喘颗粒在慢性肺源性心脏病（COPD）缓解期的治疗中的效果。方法：选取60例COPD缓解期患者，随机分为两组，每组30人。对照组给予常规西医治疗，实验组在此基础上加用参芪平喘颗粒。比较两组患者的临床疗效、生活质量评分及不良反应发生率。结果：实验组的总有效率为90%，明显高于对照组的70%。实验组患者在生活质量评分方面也显著优于对照组。实验组的不良反应发生率为10%，明显低于对照组的30%。结论：参芪平喘颗粒能有效改善COPD缓解期患者的临床症状，提高生活质量，且安全性高，值得临床推广使用。【关键词】参芪平喘颗粒；慢性肺源性心脏病；缓解期；临床疗效；生活质量；不良反应【Abstract】Objective:ToinvestigatetheeffectofShenqiPingchuanGranulesinthetreatmentofchronicobstructivepulmonarydisease(COPD)remissionphase.Methods:Atotalof60patientswithCOPDremissionphasewereselectedandrandomlydividedintotwogroups,eachcontaining30patients.ThecontrolgroupwasgivenconventionalWesternmedicinetreatment,whiletheexperimentalgroupwasgivenShenqiPingchuanGranulesinadditiontotheabovetreatment.Theclinicalefficacy,qualityoflifescore,andadversereactionratewerecomparedbetweenthetwogroups.Results:Thetotaleffectiverateoftheexperimentalgroupwas90%,significantlyhigherthanthatofthecontrolgroup(70%).Thequalityoflifescoreoftheexperimentalgroupwasalsosignificantlybetterthanthatofthecontrolgroup.Theadversereactionrateoftheexperimentalgroupwas10%,significantlylowerthanthatofthecontrolgroup(30%).Conclusion:ShenqiPingchuanGranulescaneffectivelyimprovetheclinicalsymptomsofpatientswithCOPDremissionphase,improvethequalityoflife,andhaveahighsafety,whichisworthpromotingandusinginclinicalpractice.【Keywords】ShenqiPingchuanGranules;Chronicobstructivepulmonarydisease;Remissionphase;Clinicalefficacy;Qualityoflife;Adversereaction銆怉bstract銆慭nObjective:ToinvestigatetheeffectofShenqiPingchuanGranulesinthetreatmentofchronicobstructivepulmonarydisease(COPD)remissionphase.Methods:Atotalof60patientswithCOPDremissionphasewereselectedandrandomlydividedintotwogroups,eachcontaining30patients.ThecontrolgroupwasgivenconventionalWesternmedicinetreatment,whiletheexperimentalgroupwasgivenShenqiPingchuanGranulesinadditiontotheabovetreatment.Theclinicalefficacy,qualityoflifescore,andadversereactionratewerecomparedbetweenthetwogroups.Results:Thetotaleffectiverateoftheexperimentalgroupwas90%,significantlyhigherthanthatofthecontrolgroup(70%).Thequalityoflifescoreoftheexperimentalgroupwasalsosignificantlybetterthanthatofthecontrolgroup.Theadversereactionrateoftheexperimentalgroupwas10%,significantlylowerthanthatofthecontrolgroup(30%).Conclusion:ShenqiPingchuanGranulescaneffectivelyimprovetheclinicalsymptomsofpatientswithCOPDremissionphase,improvethequalityoflife,andhaveahighsafety,whichisworthpromotingandusinginclinicalpractice.